C4 Therapeutics Inc. (CCCC)
3.75
0.25 (7.14%)
At close: Jan 14, 2025, 3:59 PM
3.71
-1.07%
Pre-market Jan 15, 2025, 05:24 AM EST
undefined% (undefined)
| Bid | 3.7 |
| Market Cap | 264.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -2.19 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.88 |
| Volume | 845,335 |
| Avg. Volume (20D) | 1,433,470 |
| Open | 3.56 |
| Previous Close | 3.50 |
| Day's Range | 3.55 - 3.85 |
| 52-Week Range | 3.38 - 11.88 |
| Beta | undefined |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma an...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 145
Stock Exchange NASDAQ
Ticker Symbol CCCC
Website https://www.c4therapeutics.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CCCC stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 166.67% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
C4 Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of $3.60M, reflecting a 10.40% YoY growth and earnings per share of -0.37, making a -45.59% decrease YoY.
Analysts project revenue of $3.60M, reflecting a 10.40% YoY growth and earnings per share of -0.37, making a -45.59% decrease YoY.
4 months ago ·
Source
+13.79%
C4 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
